论文部分内容阅读
探讨ＩＬ－２／ＬＡＫ细胞与放疗和／或化疗联合治疗晚期恶性肿瘤的价值。方法：本组共３０例，其中单纯ＩＬ－２／ＬＡＫ细胞治疗 ５例（包括 ２例ＴＩＬ细胞胸腹腔灌注），ＩＬ－２／ＬＡＫ细胞联合放疗１８例（包括 １例动脉灌注），ＩＬ－２／ＬＡＫ细胞联合化疗４例（包括１例动脉灌注），ＩＬ－２／ＬＡＫ细胞联合放疗和化疗３例。结果：完全缓解率２０．０％（６／３０），总有效率 ５０．０％（１５／３０），其中单纯ＩＬ－２／ＬＡＫ治疗有效率 ２０．０％（１／５），联合治疗有效率 ５６．０％（１４／２５）。２例 Ｋａｐｏｓｉｓ’ｓ肉瘤采用ＩＬ－２／ＬＡＫ细胞联合放、化疗均达完全缓解，１例乳腺癌术后大量胸水用 ＴＩＬ细胞＋ＩＬ－２治疗达完全缓解。结论：ＩＬ－２／ＬＡＫ细胞是有效的肿瘤过继性免疫疗法，和放、化疗联合应用可能有助于提高疗效。
To investigate the value of IL-2 / LAK cells combined with radiotherapy and / or chemotherapy in the treatment of advanced malignant tumors. Methods: A total of 30 cases were treated with IL-2 / LAK cells in 5 cases (including 2 cases of TIL cells by thoracic and abdominal cavity perfusion), IL-2 / LAK cells combined with radiotherapy in 18 cases (including 1 case of arterial perfusion) 2 / LAK cells combined chemotherapy in 4 cases (including 1 case of arterial perfusion), IL-2 / LAK cells combined with radiotherapy and chemotherapy in 3 cases. Results: The complete remission rate was 20.0% (6/30) and the total effective rate was 50.0% (15/30). The effective rate of simple IL-2 / LAK treatment was 20.0% (1/5) Efficiency 56.0% (14/25). 2 cases of Kaposis’s sarcoma with IL-2 / LAK cells combined radiotherapy and chemotherapy are up to complete remission, a large number of cases of breast cancer with TIL cells + IL-2 after treatment of complete remission. Conclusion: IL-2 / LAK cells are effective tumor adoptive immunotherapy, combined with radiotherapy and chemotherapy may help to improve the curative effect.